Last reviewed · How we verify

Argimate — Competitive Intelligence Brief

Argimate (ARGININE GLUTAMATE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: arginine glutamate. Area: Cardiovascular.

phase 3 arginine glutamate Nitric oxide synthase, inducible Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Argimate (ARGININE GLUTAMATE). Arginate works by increasing the production of nitric oxide, a molecule that helps to relax blood vessels and improve blood flow.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Argimate TARGET ARGININE GLUTAMATE phase 3 arginine glutamate Nitric oxide synthase, inducible
R-Gene 10 ARGININE Pfizer marketed arginine hydrochloride Nitric oxide synthase, inducible 1973-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) marketed Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortisol Cortisol University of Zurich marketed Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (arginine glutamate class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Argimate — Competitive Intelligence Brief. https://druglandscape.com/ci/arginine-glutamate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing